Süer Selma GÖKMEN, Reyhan YILDIZ, ERHAN TABAKOĞLU, Gündeniz ALTIAY, Ebru YAVUZ, Şendoğan GÜLEN

Akciğer kanserli hastalarda eritrosit arginaz aktivitesi

Amaç: Bu çalışmada, akciğer kanserli hastalarda kanda eritrosit arginaz aktivitesi ve hücre tipi ve ekstrapulmoner metastazın bu aktiviteye etkisi incelendi. Hastalar ve Yöntemler: Çalışmaya akciğer kanserli 46 hasta (ort. yaş 63.1) ve sağlıklı 29 birey (ort. yaş 57.2) alındı. Eritrosit arginaz aktivitesi Geyer ve Dabich yöntemi ile ölçüldü. Ayrıca, küçük hücreli akciğer kanserli 15 hasta, küçük hücreli dışı akciğer kanserli 31 hasta, ekstrapulmoner metastazı olan 23 hasta ve metastazı olmayan 23 hastanın eritrosit arginaz aktiviteleri karşılaştırıldı. Bulgular: Sağlıklı kontroller ile karşılaştırıldığında, akciğer kanserli tüm hastaların (p

Anahtar Kelimeler:

Karsinom, küçük hücreli, Akciğer neoplazmları, Arginaz, Karsinom, küçük hücreli dışı akciğer, Neoplazm metastazı

Erythrocyte arginase activity in lung cancer patients

Objectives: We investigated blood erythrocyte arginase activity in lung cancer patients and the effect of cell type and extrapulmonary metastasis on this activity. Patients and Methods: The study included 46 lung cancer patients (mean age 63.1 years) and 29 healthy subjects (mean age 57.2 years). Erythrocyte arginase activity was determined with the use of the Geyer-Dabich method. Erythrocyte arginase activity was compared between patients with small cell lung cancer (n=15), non-small cell lung cancer (n=31), extrapulmonary metastases (n=23), and no metastasis (n=23). Results: Compared to healthy controls, erythrocyte arginase activity was significantly increased in all lung cancer patients (p<0.01), and in patient groups with small cell lung cancer (p<0.05), non-small cell lung cancer (p<0.01), extrapulmonary metastases (p<0.01), and no metastasis (p<0.01). On the other hand, erythrocyte arginase activity did not differ significantly between patients with small cell lung cancer and non-small cell lung cancer, and between patients with and without extrapulmonary metastases. Conclusion: Our data suggest that, compared to healthy subjects, erythrocyte arginase activity is significantly increased in lung cancer patients, with no additional effect of cell type or extrapulmonary metastases.

Keywords:

Carcinoma, Small Cell, Lung Neoplasms, Arginase, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis,

PDF

___

1. Beruter J, Colombo JP, Bachmann C. Purification and properties of arginase from human liver and erythrocytes. Biochem J 1978;175:449-54.
2. Colombo JP, Konarska L. Arginase. In: Methods of enzymatic analysis. Bergmeyer HU, editor. 1st ed. Verlag Chemie: Basel Weinheim Dearfield Beach; 1984. p. 285-94.
3. Straus B, Borcic O. Inhibitory action of some amino acids on arginase from human liver, kidney, mammary gland and erythrocytes. Acta Pharm Jugosl 1976;26:149-53.
4. Redmond AF, Rothberg S. Arginase activity and other cellular events associated with epidermal hyperplasia. J Cell Physiol 1978;94:99-104.
5. Box VL, Brown VK. Comparison of the arginase activities of skin from some mammalian species. Comp Biochem Physiol B 1973;46:847-50.
6. Yip MC, Knox WE. Function of arginase in lactating mammary gland. Biochem J 1972;127:893-9.
7. Currie GA. Activated macrophages kill tumour cells by releasing arginase. Nature 1978;273:758-9.
8. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984;53:749-90.
9. Morgan DM. Polyamines. Essays Biochem 1987;23:82-115.
10. Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986;234:249-62.
11. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982;243:212-21.
12. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981;19:1-20.
13. Clifford A, Morgan D, Yuspa SH, Soler AP, Gilmour S. Role of ornithine decarboxylase in epidermal tumorigenesis. Cancer Res 1995;55:1680-6.
14. Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, et al. Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res 1999;5:2035-41.
15. Mafune K, Tanaka Y, Mimori K, Mori M, Takubo K, Makuuchi M, et al. Increased expression of ornithine decarboxylase messenger RNA in human esophageal carcinoma. Clin Cancer Res 1999;5:4073-8.
16. Patchett SE, Alstead EM, Butruk L, Przytulski K, Farthing MJ. Ornithine decarboxylase as a marker for premalignancy in the stomach. Gut 1995;37:13-6.
17. Elgun S, Keskinege A, Yilmaz E, Baltaci S, Beduk Y. Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer. Int Urol Nephrol 1999;31:95-9.
18. Harris BE, Pretlow TP, Bradley EL Jr, Whitehurst GB, Pretlow TG 2nd. Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Res 1983;43:3008-12.
19. Wu CW, Chi CW, Lin EC, Lui WY, P'eng FK, Wang SR, et al. Serum arginase level in patients with gastric cancer. J Clin Gastroenterol 1994;18:84-5.
20. Leu SY, Wang SR. Clinical significance of arginase in colorectal cancer. Cancer 1992;70:733-6.
21. del Ara RM, Gonzalez-Polo RA, Caro A, del Amo E, Palomo L, Hernandez E, et al. Diagnostic performance of arginase activity in colorectal cancer. Clin Exp Med 2002;2:53-7.
22. Konarska L, Widzynska I, Zienkiewicz H, Sulek K. Arginase activity alterations in peripheral blood lymphocytes in the human chronic lymphocytic leukemia. Acta Biochim Pol 1993;40:160-3.
23. Porembska Z, Luboinski G, Chrzanowska A, Mielczarek M, Magnuska J, Baranczyk-Kuzma A, et al. Arginase in patients with breast cancer. Clin Chim Acta 2003;328:105-11.
24. Straus B, Cepelak I, Festa G. Arginase, a new marker of mammary carcinoma. Clin Chim Acta 1992;210:5-12.
25. Gokmen SS, Aygit AC, Ayhan MS, Yorulmaz F, Gulen S. Significance of arginase and ornithine in malignant tumors of the human skin. J Lab Clin Med 2001;137:340-4.
26. Gökmen SS, Yörük Y, Yorulmaz F, Gülen S. Küçük hücreli dışı akciğer kanserli hastalarda doku arginaz aktivitesi. T.Ü. Tıp Fakültesi Dergisi 1999;16: 9-12.
27. Prager D, Cameron R, Ford J, Figlin R. Bronchogenic carcinoma. In: Murray JF, Nadel JA, Mason RJ, Boushey HA, editors. Textbook of Respiratory Medicine. Vol 2, 3rd ed. Philadelphia: WB Saunders Company; 2000. p. 1415-51.
28. Geyer JW, Dabich D. Rapid method for determination of arginase activity in tissue homogenates. Anal Biochem 1971;39:412-7.
29. Ohtake A, Takiguchi M, Shigeto Y, Amaya Y, Kawamoto S, Mori M, et al. Structural organization of the gene for rat liver-type arginase. J Biol Chem 1988;263:2245-9.
30. Gotoh T, Araki M, Mori M. Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem Biophys Res Commun 1997;233:487-91.
31. Scalabrino G, Ferioli ME. Polyamines in mammalian tumors. Part I. Adv Cancer Res 1981;35:151-268.
32. Scalabrino G, Ferioli ME. Polyamines in mammalian tumors. Part II. Adv Cancer Res 1982;36:1-102.
33. Janne J, Poso H, Raina A. Polyamines in rapid growth and cancer. Biochim Biophys Acta 1978;473:241-93.
34. Tutton PJ, Barkla DH. Comparison of the effects of an ornithine decarboxylase inhibitor on the intestinal epithelium and on intestinal tumors. Cancer Res 1986;46(12 Pt 1):6091-4.
35. Rothberg S, Van Scott EJ. Evaluation of arginase activity in normal epidermal tissue and pathological stratum corneum. J Invest Dermatol 1958;31:263-8.
36. Remesar X, Arola L, Palou A, Alemany M. Arginase activity during pregnancy and lactation. Horm Metab Res 1984;16:468-70.
37. Suer Gokmen S, Yoruk Y, Cakir E, Yorulmaz F, Gulen S. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem Biophys 1999;17:125-31.
38. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigenspecific T-cell responses. Cancer Res 2004;64:5839-49.
39. Wu JT. Diagnosis and management of cancer using serologic tumor markers. In: Henry JB, editor. Clinical Diagnosis and Management by Laboratory Methods. 19th ed. Philadelphia: WB Saunders Company; 1966. p. 1064-80.
40. Porembska Z, Skwarek A, Mielczarek M, Baranczyk- Kuzma A. Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma. Cancer 2002;94:2930-4.
41. Margalit O, Eisenbach L, Amariglio N, Kaminski N, Harmelin A, Pfeffer R, et al. Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. Br J Cancer 2003;89:314-9.
42. Porembska Z, Skwarek A, Chrzanowska A, Mielczarek M, Nyckowski P, Baranczyk-Kuzma A, et al. Arginase as a marker of cancerogenesis. III. Comparison of arginase activity with CEA and Ca 19-9 in liver metastases of colorectal cancer. Pol Merkuriusz Lek 2004;16:31-3. [Abstract]